Validation of sputum Gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia: a prospective observational study

BMC Infectious Diseases

Tomoo Kishaba²  Hitoshi Tamaki²  Kiyoshi Kinjo¹  Shin Yamashiro²  Hajime Fukuyama² 

[1] Department of General Internal Medicine, Okinawa Chubu Hospital, 281 Miyazato, Uruma, Okinawa, Japan;Department of Respiratory Medicine, Okinawa Chubu Hospital, 281 Miyazato, Uruma, Okinawa, Japan

关键词: Healthcare-associated pneumonia;    Community-acquired pneumonia;    Gram stain;    Sputum;    Pneumonia;   

Others  :  1122211
DOI  :  10.1186/1471-2334-14-534

 received in 2014-05-18, accepted in 2014-09-15,  发布年份 2014

【 摘 要 】

Background

The usefulness of sputum Gram stain in patients with community-acquired pneumonia (CAP) is controversial. There has been no study to evaluate the diagnostic value of this method in patients with healthcare-associated pneumonia (HCAP). The purpose of this study was to evaluate the usefulness of sputum Gram stain in etiological diagnosis and pathogen-targeted antibiotic treatment of CAP and HCAP.

Methods

We conducted a prospective observational study on hospitalized patients with pneumonia admitted to our hospital from August 2010 to July 2012. Before administering antibiotics on admission, Gram stain was performed and examined by trained physicians immediately after sputum samples were obtained. We analyzed the quality of sputum samples and the diagnostic performance of Gram stain. We also compared pathogen-targeted antibiotic treatment guided by sputum Gram stain with empirical treatment.

Results

Of 670 patients with pneumonia, 328 were CAP and 342 were HCAP. Sputum samples were obtained from 591 patients, of these 478 samples were good quality. The sensitivity and specificity of sputum Gram stain were 62.5% and 91.5% for Streptococcus pneumoniae, 60.9% and 95.1% for Haemophilus influenzae, 68.2% and 96.1% for Moraxella catarrhalis, 39.5% and 98.2% for Klebsiella pneumoniae, 22.2% and 99.8% for Pseudomonas aeruginosa, 9.1% and 100% for Staphylococcus aureus. The diagnostic yield decreased in patients who had received antibiotics or patients with suspected aspiration pneumonia. Pathogen-targeted treatment provided similar efficacy with a decrease in adverse events compared to empirical treatment.

Conclusions

Sputum Gram stain is highly specific for the etiologic diagnosis and useful in guiding pathogen-targeted antibiotic treatment of CAP and HCAP.

【 授权许可】

   
2014 Fukuyama et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 1.

【 参考文献 】

• [1]Woodhead MA, Arrowsmith J, Chamberlain-Webber R, Wooding S, Williams I: The value of routine microbial investigation in community-acquired pneumonia. Respir Med 1991, 85:313-317.
• [2]Theerthakarai R, El-Halees W, Ismail M, Solis RA, Khan MA: Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest 2001, 119:181-184.
• [3]Ewig S, Schlochtermeier M, Göke N, Niederman MS: Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002, 121:1486-1492.
• [4]Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG, Infectious Diseases Society of America; American Thoracic Society: Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72.
• [5]Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases: Guidelines for the management of adult lower respiratory tract infections - full version. Clin Microbiol Infect 2011, 17(Suppl 6):E1-59.
• [6]Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA, Pneumonia Guidelines Committee of the BTS Standards of Care Committee: BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64(Suppl 3):iii1-55.
• [7]Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, Schouten JA, Degener JE, Janknegt R, Verheij TJ, Sachs AP, Prins JM, Dutch Working Party on Antibiotic Policy; Dutch Association of Chest Physicians: SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. Neth J Med 2012, 70:90-101.
• [8]Miyashita N, Matsushima T, Oka M, Japanese Respiratory Society: The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med 2006, 45:419-428.
• [9]American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
• [10]Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
• [11]Barrett-Connor E: The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am Rev Respir Dis 1971, 103:845-848.
• [12]Lentino JR, Lucks DA: Nonvalue of sputum culture in the management of lower respiratory tract infections. J Clin Microbiol 1987, 25:758-762.
• [13]Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S: The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003, 123:1142.
• [14]Waterer GW, Wunderink RG: The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001, 95:78-82.
• [15]van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Jansen HM, Boersma WG: Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005, 24:241-249.
• [16]Japanese Respiratory Society: The Japanese respiratory society guidelines for the management of hospital-acquired pneumonia in adults. Respirology 2009, 14(Suppl 2):S1-71.
• [17]Rosón B, Carratalà J, Verdaguer R, Dorca J, Manresa F, Gudiol F: Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000, 31:869-874.
• [18]Musher DM, Montoya R, Wanahita A: Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004, 39:165-169.
• [19]Anevlavis S, Petroglou N, Tzavaras A, Maltezos E, Pneumatikos I, Froudarakis M, Anevlavis E, Bouros D: A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect 2009, 59:83-89.
• [20]Reed WW, Byrd GS, Gates RH Jr, Howard RS, Weaver MJ: Sputum gram's stain in community-acquired pneumococcal pneumonia. A Meta-Anal West J Med 1996, 165:197-204.
• [21]García-Vázquez E, Marcos MA, Mensa J, de Roux A, Puig J, Font C, Francisco G, Torres A: Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004, 164:1807-1811.
• [22]Miyashita N, Shimizu H, Ouchi K, Kawasaki K, Kawai Y, Obase Y, Kobashi Y, Oka M: Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. Med Sci Monit 2008, 14:CR171-176.
• [23]Brito V, Niederman MS: Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 2009, 22:316-325.
• [24]Ewig S, Welte T, Chastre J, Torres A: Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010, 10:279-287.
• [25]van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W, Jansen HM, Boersma WG: Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005, 60:672-678.
• [26]Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, Cely CM, Ford KD, Scerpella EG, Ramirez JA, Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators: Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011, 11:181-189.
• [27]Gould IM: A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999, 43:459-465.
• [28]Fine MJ, Orloff JJ, Rihs JD, Vickers RM, Kominos S, Kapoor WN, Arena VC, Yu VL: Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia. J Gen Intern Med 1991, 6:189-198.
• [29]Bartlett JG: Decline in microbial studies for patients with pulmonary infections. Clin Infect Dis 2004, 39:170-172.
• [30]Wigton RS, Alguire P, American College of Physicians: The declining number and variety of procedures done by general internists: a resurvey of members of the American College of Physicians. Ann Intern Med 2007, 146:355-360.